Yale University
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
This study is being conducted to evaluate the effects of 30 days of intermittently microdosed psilocybin in a parallel arm double-blind manner on mood, cognition, subjective well-being and structural/functional MRI compared to placebo, using validated psychological assessments and cognitive tests. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences. Demonstrating significant results in a population of healthy psychedelic n…
Inclusion Criteria: * No history of psychedelic use OR * No use within 10 years, less than or equal to 7x in life OR * No use within 5 years, less than or equal to 3x in life * Able to read, speak, and understand English * Able and willing to provide written informed consent, and willing to commit to study protocol * Women of childbearing potential must be on a highly effective birth control method * Must have smartphone compatible with mindLAMP app Exclusion Criteria: * Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment * Current mood,…
2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks
0mg matching capsules, provided three times weekly for four weeks
Arctuva estimate
Verify or correct the compensation shown for this listing.